MeiraGTx Holdings Plc (MGTX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Summary

MeiraGTx Holdings Plc (MeiraGTx) is an independent clinical-stage gene therapy company that focuses on the development of therapeutics for the treatment of eye, salivary gland and neurodegenerative diseases. The companys pipeline of preclinical and research programs include AAV-CNGB3, for achromatopsia; AAV-RPGR, for X-linked retinitis pigmentosa; AAV-RPE65, for RPE65-Deficiency; AAV-AQP1, for xerostomia and sjogrens syndrome; and AAV-UPF1, for amyotrophic lateral sclerosis (ALS) among others. MeiraGTx works in collaboration with leading institutions to develop next-generation gene therapies. The company has presence in the US, the UK and the Netherlands. MeiraGTx is headquartered in New York, the US.

MeiraGTx Holdings Plc (MGTX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the companys Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

it derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the companys financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the companys major financial deals. Each such deal has a brief Summary, deal type, deal rationale; and deal financials and target Companys (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the companys operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the companys financial deals that enable you to understand the companys expansion/divestiture and fund requirements
- The profile enables you to analyze the companys financial deals by region, by year, by business segments and by type, for a five year period.

Understand the companys business segments expansion / divestiture strategy
- The profile presents deals from the companys core business segments perspective to help you understand its corporate strategy.

Access elaborate information on the companys recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a Summary of each deal, deal type, deal rationale, deal financials and Target Companys key financial metrics and ratios.

Equip yourself with detailed information about the companys operations to identify potential customers and suppliers.
- The profile analyzes the companys business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.


List of Tables 4
List of Figures 4
MeiraGTx Holdings Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
MeiraGTx Holdings Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
MeiraGTx Holdings Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
MeiraGTx Holdings Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
MeiraGTx Holdings Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
MeiraGTx Holdings Plc, Pharmaceuticals & Healthcare, Deal Details 10
Partnerships 10
MeiraGTx Enters into Collaboration Agreement with Janssen Pharma 10
MeiraGTx and eXmoor pharma Enter into Agreement 11
Oxford Genetics Enters into Agreement with MeiraGTx 12
MeiraGTx Enters into Agreement with Weill Cornell Medicine 13
MeiraGTx Enters into Agreement with Weill Cornell Medicine and LSU Health Shreveport 14
Athena Vision Enters into Agreement with MeiraGTx 15
Licensing Agreements 16
MeiraGTx Enters into Licensing Agreement with UCL Business 16
MeiraGTx Enters into Licensing Agreement with UCL Business 17
Equity Offering 18
MeiraGTx Raises USD75 Million in IPO of Shares 18
Acquisition 19
MeiraGTx Acquires Vector Neurosciences 19
MeiraGTx Acquires Kadmon Gene Therapy from Kadmon 20
MeiraGTx Holdings Plc - Key Competitors 21
MeiraGTx Holdings Plc - Key Employees 22
MeiraGTx Holdings Plc - Locations And Subsidiaries 23
Head Office 23
Other Locations & Subsidiaries 23
Recent Developments 24
Legal and Regulatory 24
Jun 21, 2018: MeiraGTx Announces MHRA Grants MIA (IMP) License for cGMP Manufacturing Facility in London, UK 24
Government and Public Interest 25
Feb 01, 2017: MeiraGTx Awarded Target ALS Grant For Its NMD-Based Therapy for ALS 25
Product News 26
08/24/2017: MeiraGTx Provides Clinical Trial Update for Leber Congenital Amaurosis Type 2 Gene Therapy Program 26
Product Approvals 27
Dec 07, 2017: MeiraGTx Receives Rare Pediatric Disease Designation for A001 for the Treatment of Lebers Congenital Amaurosis and Treats First Pediatric Patient in Phase I/II Clinical Trial 27
Clinical Trials 28
Oct 17, 2017: MeiraGTx Presents Preclinical Data on AAV2/5-OPTIRPE65 for the Treatment of Lebers Congenital Amaurosis at ESGCT 2017 Congress in Berlin 28
Aug 24, 2017: MeiraGTx Provides Clinical Trial Update for Achromatopsia Gene Therapy Program 29
Aug 24, 2017: MeiraGTx Provides Clinical Trial Update for X-Linked Retinitis Pigmentosa Gene Therapy Program 30
Appendix 31
Methodology 31
About GlobalData 31
Contact Us 31
Disclaimer 31

List Of Tables


MeiraGTx Holdings Plc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
MeiraGTx Holdings Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
MeiraGTx Holdings Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
MeiraGTx Holdings Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
MeiraGTx Holdings Plc, Deals By Therapy Area, 2012 to YTD 2018 8
MeiraGTx Holdings Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
MeiraGTx Enters into Collaboration Agreement with Janssen Pharma 10
MeiraGTx and eXmoor pharma Enter into Agreement 11
Oxford Genetics Enters into Agreement with MeiraGTx 12
MeiraGTx Enters into Agreement with Weill Cornell Medicine 13
MeiraGTx Enters into Agreement with Weill Cornell Medicine and LSU Health Shreveport 14
Athena Vision Enters into Agreement with MeiraGTx 15
MeiraGTx Enters into Licensing Agreement with UCL Business 16
MeiraGTx Enters into Licensing Agreement with UCL Business 17
MeiraGTx Raises USD75 Million in IPO of Shares 18
MeiraGTx Acquires Vector Neurosciences 19
MeiraGTx Acquires Kadmon Gene Therapy from Kadmon 20
MeiraGTx Holdings Plc, Key Competitors 21
MeiraGTx Holdings Plc, Key Employees 22
MeiraGTx Holdings Plc, Subsidiaries 23

List Of Figures


MeiraGTx Holdings Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
MeiraGTx Holdings Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
MeiraGTx Holdings Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
MeiraGTx Holdings Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
MeiraGTx Holdings Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
MeiraGTx Holdings Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
MeiraGTx Holdings Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
MeiraGTx Holdings Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

MeiraGTx Holdings Plc (MGTX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

MeiraGTx Holdings Plc (MeiraGTx) is an independent clinical-stage gene therapy company that focuses on the development of therapeutics for the treatment of eye, salivary gland and neurodegenerative diseases. The companys

USD 250 View Report

Immunodiagnostic Systems Holdings plc (IDH) - Product Pipeline Analysis, 2019 Update

Immunodiagnostic Systems Holdings plc (IDS) is an in-vitro diagnostic solution provider that develops, manufactures and markets immunoassays and automated immunoanalyser technologies. The company conducts research in the areas of bone

USD 750 View Report

Hill & Smith Holdings Plc - Strategy, SWOT and Corporate Finance Report

Hill & Smith Holdings Plc - Strategy, SWOT and Corporate Finance ReportHill & Smith Holdings Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data

USD 175 View Report

Fill The Form For Sample Request

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available